Skip to content
  • Add anything here or just remove it...
ImpentriImpentri
  • Home
  • About
  • Imatinib for COVID-19
  • News
  • Exvastat
  • Contact

Design

Another Print Package

Design

FL3 Print Package

Design

Awesome Pencil Poster

Design

Portfolio typography

Design

Flatsome Poster Print

Design

Magazine

Design

  • Home
  • About
  • Imatinib for COVID-19
  • News
  • Exvastat
  • Contact

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101005142.

This Joint Undertaking receives support from the European Union’s Horizon 2020
research and innovation programme and EFPIA.

IMPENTRI IMI2Follow

IMPENTRI IMI2
Imi2Impentri
10 May

International COVID-19 trial to restart with focus on immune responses https://www.nature.com/articles/d41586-021-01090-z

Reply on Twitter 1391712907021406210Retweet on Twitter 1391712907021406210Like on Twitter 13917129070214062102Twitter 1391712907021406210
Imi2Impentri
3 Feb

Excited to announce that the clinical trial of Impentri in patients with #COVID19 associated ARDS has been approved. Hope to recruit the first patient soon.

Reply on Twitter 1357019438252515328Retweet on Twitter 1357019438252515328Like on Twitter 13570194382525153283Twitter 1357019438252515328
Imi2Impentri
14 Dec

Two highly relevant, recent @Nature papers have been published to deepen our understanding of the potential benefit of imatinib for the treatment of #Covid_19:
https://doi.org/10.1038/s41586-020-2901-9
and https://doi.org/10.1038/s41586-020-03065-y

Reply on Twitter 1338417061589086208Retweet on Twitter 1338417061589086208Like on Twitter 1338417061589086208Twitter 1338417061589086208
Load More...
Copyright 2021 © Exvastat Ltd
  • Home
  • About
  • Imatinib for COVID-19
  • News
  • Exvastat
  • Contact
    • WooCommerce not Found